New hope for Tough-to-Treat blood cancer patients
NCT ID NCT07460362
Summary
This study is testing whether a combination of two drugs, glofitamab and lenalidomide, can help control a hard-to-treat type of blood cancer called mantle cell lymphoma. It is for patients whose cancer has come back or stopped responding to previous treatments, including a specific type of drug called a BTK inhibitor. The main goal is to see how many patients' cancers shrink or disappear after receiving this new combination therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.